Venetoclax: Phase I data

Data from 34 patients with diffuse large B cell lymphoma (DLBCL) in an open-label, dose-escalation Phase I trial showed that 200-1,200 mg/day doses of oral venetoclax led to an ORR of 15%, including 3...